The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK, AstraZeneca rivalry takes centre stage at cancer conference

Thu, 26th Sep 2019 10:04

* British firms to square off at oncology meeting

* Investors seek insights from Zejula, Lynparza trials

* Readouts could be indicative of size of future markets

By Ludwig Burger

Sept 26 (Reuters) - GlaxoSmithKline and AstraZeneca
will each present trial data on a promising new class of
drugs against ovarian cancer on Saturday as Britain's top
drugmakers compete to burnish their oncology credentials.

They will unveil results of studies for rival drugs to block
a cancer's ability to repair its genetic code, presenting their
findings at the European Society For Medical Oncology's (ESMO)
annual conference in Barcelona over the weekend.

Both companies have already flagged that their respective
drug candidates, part of a class known as PARP inhibitors, did
well in staving off a return of ovarian cancer in women that had
responded to initial standard treatment.

GSK and Astra, which are also competing in respiratory
drugs, have held back full trial details for the ESMO event.

Analysts and investors will be looking for clues as to how
large a patient group will likely benefit in the future.

Many cancer cells have a limited ability to make DNA repairs
during cell division, as healthy cells would. This feature, one
of the hallmarks of cancer, makes tumours genetically volatile
and helps them develop resistance to treatment over time.

Drugmakers try to use that to their advantage with PARP
inhibitors that block what is left of the DNA repair mechanism
so cancer cells fail to replicate and a tumour cannot sustain
itself.

The drug class was initially targeted at patients that had a
mutation in BRCA genes but the two British drugmakers are keen
to add to evidence that wider patient groups can be helped with
their respective drugs.

"The utility of the PARP inhibitors could be much broader
than just patients that have a tumour with the BRCA mutation,"
said John Bowler, who manages more than $300 million in
healthcare and biotech stocks at asset manager Schroders.

"That becomes relevant when you start thinking about the
drugs' role in other tumour types like prostate cancer and
breast cancer where the incidence of new patients each year is
much greater than in ovarian cancer," he said.

GlaxoSmithKline cancer treatment Zejula slowed the
progression of ovarian cancer in a late-stage study called
PRIMA, the British drugmaker said in a release of headline data
in July.

The drug originated in the labs of U.S. cancer specialist
Tesaro, which GSK acquired for $5.1 billion in December. The
deal, masterminded by Chief Scientific Officer Hal Barron, was
seen as too pricey by many analysts.

"The outcome of this trial is the key test of Hal Barron
saying this will justify the deal on its own if it comes good.
This would be vindication for the first big acquisition that he
has done for Glaxo," said Bowler of Schroders.

Astra and its U.S. development partner Merck & Co
announced on Aug. 14 that their joint drug Lynparza was shown to
slow the progression of ovarian cancer that had started to
spread in the body, in the so-called PAOLA-1 trial.

An inclusion requirement for trial participants had been a
successful initial treatment with chemotherapy and Roche's
Avastin following a diagnosis of advanced ovarian cancer.

Analysts see Astra and Merck's Lynparza in the lead with an
average annual sales estimate of $3.1 billion in 2023. GSK's
Zejula is seen at about 870 million pounds ($1.1 billion) in
revenues that year.

Two more PARP inhibitors, Pfizer's Talzenna and Clovis
Oncology's Rubraca, are seen as further behind.

($1 = 0.8039 pounds)
(Editing by Edmund Blair)

More News
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.